Published in

Future Medicine, Journal of Comparative Effectiveness Research, 6(10), p. 509-517, 2021

DOI: 10.2217/cer-2020-0275

Links

Tools

Export citation

Search in Google Scholar

Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study

Journal article published in 2021 by Pedro Ricardo Kömel Pimenta ORCID, Michael Ruberson Ribeiro da Silva ORCID, Jéssica Barreto Ribeiro dos Santos ORCID, Adriana Maria Kakehasi ORCID, Francisco de Assis Acurcio ORCID, Juliana Alvares-Teodoro ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Aim: To evaluate the effectiveness and safety of anti-TNF drugs for ankylosing spondylitis. Materials & methods: A prospective cohort study was performed at a pharmacy in the Brazilian Public Health System. Effectiveness by Bath Ankylosing Spondylitis Disease Activity Index, functionality by Health Assessment Questionnaire Disability Index, quality of life by European Quality of Life Five-Dimensions and safety was assessed at 6 and 12 months of follow-up. Results: About 160 patients started the treatment with adalimumab, etanercept or infliximab. There was a statistically significant improvement in disease activity, functionality and quality of life at 6 and 12 months (p < 0.05). Conclusion: This real-world study has shown that anti-TNF drugs are effective and well tolerated for ankylosing spondylitis patients.